U.S. markets closed

Obalon Therapeutics, Inc. (OBLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
1.5600-0.1400 (-8.24%)
At close: 4:00PM EST
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
Total Revenue
2,286
3,281
9,101
9,914
Cost of Revenue
2,259
2,950
5,423
4,829
Gross Profit
27
331
3,678
5,085
Operating Expense
20,068
23,561
40,643
39,476
Operating Income
-20,041
-23,230
-36,965
-34,391
Net Non Operating Interest Income Expense
-160
-385
-226
-135
Other Income Expense
-1,722
-61
-189
-239
Pretax Income
-20,647
-23,676
-37,380
-34,765
Net Income Common Stockholders
-20,647
-23,676
-37,380
-34,765
Diluted NI Available to Com Stockholders
-20,647
-23,676
-37,380
-34,765
Basic EPS
-
-0.005
-0.0196
-0.0208
Diluted EPS
-
-0.005
-0.0196
-0.0208
Basic Average Shares
-
4,707
1,904
1,672
Diluted Average Shares
-
4,707
1,904
1,672
Total Operating Income as Reported
-20,041
-23,230
-36,965
-34,391
Total Expenses
22,327
26,511
46,066
44,305
Net Income from Continuing & Discontinued Operation
-20,647
-23,676
-37,380
-34,765
Normalized Income
-20,647
-23,676
-37,380
-34,526
Net Interest Income
-160
-385
-226
-135
EBIT
-20,041
-23,230
-36,965
-34,391
EBITDA
-19,164
-
-
-
Reconciled Cost of Revenue
2,259
2,950
5,423
4,829
Reconciled Depreciation
877
894
581
330
Net Income from Continuing Operation Net Minority Interest
-20,647
-23,676
-37,380
-34,765
Total Unusual Items Excluding Goodwill
-
-
-
-239
Total Unusual Items
-
-
-
-239
Normalized EBITDA
-19,164
-22,336
-36,384
-33,822
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0

Premium access required.

Learn more